Exploiting molecular biology for diagnosis and targeted management of pediatric low-grade gliomas
Document Type
Article
Abstract
The majority of brain tumors arising in children are low-grade gliomas. Although historically categorized together as pediatric low-grade gliomas (PLGGs), there is significant histologic and genetic diversity within this group. In general, prognosis for PLGGs is excellent, and limitation of sequelae from tumor and treatment is paramount. Advances in high-throughput genetic sequencing and gene expression profiling are fundamentally changing the way PLGGs are classified and managed. Here, we review the histologic subtypes and highlight how recent advances in elucidating the molecular pathogenesis of these tumors have refined diagnosis and prognostication. Additionally, we discuss how characterizing specific genetic alterations has paved the way for the rational use of targeted therapies that are currently in various phase clinical trials.
Publication Date
6-1-2016
Publication Title
Future Oncology
ISSN
14796694
E-ISSN
17448301
Volume
12
Issue
12
First Page
1493
Last Page
1506
PubMed ID
27072750
Digital Object Identifier (DOI)
10.2217/fon-2016-0039
Recommended Citation
Garcia, Michael A.; Solomon, David A.; and Haas-Kogan, Daphne A., "Exploiting molecular biology for diagnosis and targeted management of pediatric low-grade gliomas" (2016). Radiation Oncology. 23.
https://scholar.barrowneuro.org/radiation-oncology/23